Neubase Therapeutics Stock Filter Stocks by Fundamentals
| NBSE Stock | USD 0.43 0.01 2.38% |
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.05 | 0.05 |
NeuBase | Debt to Equity |
Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
NeuBase Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (5.74 M) | ||||
| Shares Outstanding | 3.75 M | ||||
| Shares Owned By Insiders | 13.37 % | ||||
| Shares Owned By Institutions | 12.68 % | ||||
| Number Of Shares Shorted | 149.12 K | ||||
| Price To Earning | (4.17) X | ||||
| Price To Book | 0.18 X | ||||
| EBITDA | (32.49 M) | ||||
| Net Income | (33.78 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 6 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 2.45 X | ||||
| Cash Flow From Operations | (29.01 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (18.60) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 140.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.96 | ||||
| Market Capitalization | 1.51 M | ||||
| Total Asset | 32.69 M | ||||
| Retained Earnings | (102.74 M) | ||||
| Working Capital | 20.48 M | ||||
| Current Asset | 4.14 M | ||||
| Current Liabilities | 1.6 M | ||||
| Net Asset | 32.69 M |
About NeuBase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out NeuBase Therapeutics Piotroski F Score and NeuBase Therapeutics Altman Z Score analysis. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.